• No results found

Drugs affecting calcium and bone metabolism

N/A
N/A
Protected

Academic year: 2021

Share "Drugs affecting calcium and bone metabolism"

Copied!
10
0
0

Loading.... (view fulltext now)

Full text

(1)

Drugs affecting calcium and bone metabolism

Factors which influence bone remodelling

Continuous remodelling process (0.5-1% bone loss per year, after the menopause 1-3% per year)

- Cells: osteoblasts secrete, osteoclasts break down bone matrix-recruited and activated by cytokines and hormones - Minerals: calcium and phosphate

- Cytokines: insulin-like growth factor (IGF); transforming growth factor (TGF-b); bone morphogenic protein (BMP); interleukins; TNF- embedded in the bone matrix (osteoid) - Hormones: parathyreoid hormone (PTH); the vitamin D family; oestrogens; growth hormone (GH); steroids and calcitonin

- Diet - Drugs

- Physical factors (exercise, loading)

Bone remodelling cycle

• Recruitment of OC precursors by OB-derived mediators • Differentiation to mat. multinoculated OCs by cytokines • Adherence to the trabecular bone, moving along and secreting H+ and proteolytic enzymes • Liberation of cytokines embedded in the osteoid • Consequent recruitment and activation of OBs • Osteoid and cytokine

secretion

• Osteocyte form. after being embedded in the osteoid

(2)

2

Disorders of the bone

1. Disorders of the bone structure:

- Osteoporosis: structural (microarchitectural) deterioriation and decreased bone mass

Frequent fractures

Causes: postmenopausal oestrogen defficiency, age-related deterioration, excessive thyroid hormone or glucocorticoid production/intake, rheumatoid arthritis

- Osteopenia: reduction of the mineral content of the bone - Osteomalacia and rickets (juvenile form): defects of bone

mineralization due to vitamin D deficiency

- Paget’s disease: distortion of bone resorption and remodelling processes

2. Disorders of bone mineral metabolism:

- Hypocalcaemia: hypoparathyroidism, vit. D deficiency, congenital rickets, kidney diseases

- Hypercalcaemia: hyperparathyroidism, sarcoidosis, malignancies

- Hypophosphataemia: nutritional deficiencies - Hyperphosphataemia: renal failure

Role of osteoblasts and cytokines in octeoclast activation Mechanism of antiresorptive drugs

RANK: receptor activation og nuclear factor kappa B (NF-kB)– osteoclast differentiation

and activation receptor

= OPG: osteoprotegerin (OPG) released by Obs and stromal cells; rOPG: recombinant OPG (clin. trials)

(3)

Turnover of bone minerals

I. Calcium metabolism:

- The human body contains 1000-2000 mg calcium (98% hidroxyapatite in the bones); 700 mg per day turnover - Plasma Ca 2+: 2.5 mmol/l

- Regulation of plasma Ca2+: PTH, vitamin D family; calcitonin

- GI absorption via Ca2+-binding protein whose synthesis is

regulated by calcitriol

- Urinary Ca 2+ excretion is constant – PTH and calcitriol

enhance resorption in the tubules), therefore reduce excretion

II. Phosphate metabolism:

- 1000 mg phosphate (85% in the bones)

- GI absorption is an energy-requiring process regulated by calcitriol

- Deposition in the bone as hydroxyapatite is regulated by PTH and calcitriol (mobilise calcium and phosphate from the bone matrix)

- Excretion through the kidney – PTH inhibits reabsorption

(4)

4

I. Hormones regulating bone metabolism

1. Parathormone (PTH, parathyreoid hormone):

- 84 aminoacid-containing polypeptide synthesized in parathyreoid cells and stored in vesicles

- secretion is controlled by plasma Ca2+ (low Ca2+

stimulates secretion, high Ca2+inhibits it by Ca2+–sensing

Gi protein-coupled surface receptors)

- mobilises Ca2+ from bone (OC recruitment and

activation; BUT! exogenous administration of low, intermittent doses or fragments OB activity)

- enhances tubular resorption of Ca2+ and excretion of

phosphate

- stimulates calcitriol synthesis increases GI Ca2+

absorption and mobilises Ca2+ from bone

Increases plasma Ca2+ and lower plasma phosphate

Teriparatide:

- 1-34 fragment of recombinant PTH

- anabolic on the boneincreases bone mass, structural integrity and strength, number and activity of Obs, decreases OB apoptosis

- acts via G-protein-coupled PTH-1 receptors (AC and PL activation)

- well-tolerated , nausea, dizziness, headache, joint pain, mild hypercalcaemia, orthostatic hypotension, headache might occur

- s.c. injection once a day

- Clinical use: osteoporosis; prevention and treatment of

pathological fractures

(5)

2. Vitamin D family: - preprohormone converted to active hormones • plant ergosterolD2 (ergocalciferol) • cholesterol 7-dehydrocholesterol (intestinal wall)D3 (cholecalciferol;skin by UV irradiation) 25-hydroxy-cholecalciferol (calcifediol; liver) 1,25-dihydroxy-cholecalciferol (calcitriol) 7-dehydrocholesterol kidney liver - increase Ca2+

absorption from the GI tract

- decrease renal excretion of Ca2+

mobilize Ca2+from the

bone

- activates OBs and promotes cell

(6)

6 Medical preparations: ergocalciferol, alfacalcidol, calcitriol,

19-nor-paracalcitol, doxercalciferol(less potent to cause hypercalcaemia)

- fat-soluble vitamins, given orally, bind to specific a

-globulins, accumulated in the fat, eliminated by the faeces - Side effects: hypercalcaemiaconstipation, depression,

weakness, fatigue, kidney stones, renal failure - Clinical uses:

• Vitamin D deficiencies (malabsorption, liver disease) to prevent osteomalacia

• Osteodystrophy associated with renal failure (due to decreased calcitriol)

• Hypoparathyroidism, hypocalcaemia

Plasma Ca2+levels should be monitored during therapy!

3. Calcitonin:

- secreted by specialized „C” cells of the thyroid follicles determined by the plasma Ca2+concentration

- inhibits of bone resorption by receptors on the OCs - decreases calcium and phosphate resorption in the

proximal tubules of the kidney 

Decreases plasma Ca2+

Salcatonin: synthetic salmon salmon calcitonin Synthetic (recombinant) human calcitonin

- s.c. or i.m. inj. or intranasal (200 IU/day) administration - plasma t1/2: 4-12 min, but action lasts for hours

- Side effects: local inflammation at injection site, nausea, vomiting, flush, unpleasant taste, tingling of the hands - Clinical uses: hypercalcaemia, osteoporosis (vertebral

compressions)

(7)

-4. Oestrogens: Maintaining bone integrity (during repr. cycle in women)

- inhibit cytokines that recruit Ocs - diminish bone-resorbing action of PTH 5. Glucocorticoids:

- physiological concentrations are required for OB differentiation

- excessive concentrations (pharmacological or

pathological) inhibit OB differentiation and activity + stimulate OC actionosteoporosis

6. Thyroid hormones: - Osteoid formation - OB activity

II. Hormone-like synthetic compounds

1. Tibolone:

- synthetic compound, which breaks down to an oestrogen-like, a gestagen-like and an androgen-like molecule

- Oestogen-like effects are predominant in the bones (diminish bone loss) and diminishes postmenopausal

symptoms, but does not stimulate the mammaries and the uterus

2. Raloxifen (selective oestrogen receptor modulator: SERM): - advantage over HRT: induce agonistic actions on some

systems (bone and CV system) and antagonistic on others (mammary glands and uterus)

- D-dependent increase in OB activity (IGF-I) and reduction in OC action (IL-6, IL-1, TNF↓)

- Increasing bone density (2-3% per year) and decreasing pathological risks (45-50%)

- good GI absorption, extensive first-pass metabolism (BA: 2%), wide distribution, fecal excretion, plasma t1/2: 32 h - Side effects: hot flushes, leg cramps, venous

(8)

8

III. Non-hormonal agents influencing

bone metabolism

1. Bisphosphonates: aledronate, risedronate, etidronate, clodronate, ibandronate, pamidronate, tiludronate, zoledronate(one i.v. infusion in malignancies, Paget’s disease and osteoporosis)

- enzyme-resistant analogues of pyrophosphate that inhibit OCs diminish bone resorption

- they are bound to the matrix, released slowly and ingested by OCs when they resorb bone

- Mechanism of action:

Simple structures (etidronate, clodronate): Incorporate into ATP analogues (cytotoxic ATP analogues) that are accumulate in the OCs and induce apoptosis

N-containing compounds (amin-bisphosphonates: aledronate, risedronate): interfere with the with the formation of the ruffled border at the cell-site attachment

preventing bone resorption.

They inhibit farnesyl-diphosphate synthase (an enzyme in the mevalonate pathway)prevention of the

synthesis of certain lipids involved in the activity of small GTP-ase signalling proteins necessary in the formation of the ruffled border

(9)

- Kinetics:

Given orally, but poorly absorbed i.v. injection in malignancies

50% accumulates in the bone at the site of mineralization and remains there for months

Excreted unchanged in the urine - Side effects:

GI disorders (peptic ulcers, aldronate: oesophagitis) Bone pain (etidronate: increased risk of fractures) - Clinical uses:

Prevention/treatment of postmenopausal osteoporosis (with or without oestrogens) and glucocorticoid-induced osteoporosis

Hypercalcaemia caused by malignanies Cancer metastases in bone

Paget’s disease

2. Stroncium ranelate:

- two stroncium atoms combined with organic ralenic acid carrier

- inhibits bone resorption and stimulates bone formation - Mechanism (?): stroncium is similar to calcium, absorbed on

the hydroxyapatite crystals, exchanged to calcium in the bone minerals and remain in the bone for many years - Well tolerated, diarrhea and nausea might be side-effects - effectively inhibits fractures in elderly women

Rarely used drugs: 3. Thiazide diuretics:

- decrease calcium and oxalate excretion 4. Fluoride: last choice

- Incorporated into fluoroapatite inhibit OCs and enhance the mitosis and activity of OBsincrease trabecular bone mass - Problem: very narrow therapeutic width

- Side effects: GI irritation and bleeding,

(10)

10 6. Calcium salts:

- gluconate and lactate- p.o. or i.v. (i.m. injection causes necrosis)

- carbonate: antacid, poorly absorbed, causes calcification

7. Calcimimetic compounds:

- Enhance the sensitivits of parathyreoid Ca2+-sensing receptors

- Decrease PTH secretion and reduce serum Ca2+ Type I. calcimimetics: agonists, polycations

Type II. : allosteric activators – cinacalcet (hyperparathyroidism)

References

Related documents

Faraz Sadeghi, Ahmad Kueh, Ali Bagheri Fard, and Nasim Aghili(6)In this paper the authors studied numerically the various types of human running dynamic loads

Apple, Amazon and Microsoft (but not Google) provide a “default” EULA governing the use of your company’s App, but each platform also allows you to adopt your own EULA instead —

I N HER DUNNET SKETCH "The Foreigner," one of those four afterpieces to the original Country of the Pointed Firs, 1 Sarah Orne Jewett structured a ghost.. story that is

The data suggest that children with unmedicated ADHD have faster rates of BMI growth after approximately age 10 years compared with controls with neither a history of ADHD nor

In order to monitor the effect of VMTP on serum lipid levels, concentrations of fasting serum triglyceride and cholesterol were determined after 4 weeks of treatment (at week 12)

The legitimate client is also known as the normal client in which they can directly have request from the web site until the attacker client attack the web

Given the benefits of applying emotional intelligence in sport, the aim of this research is to investigate the effectiveness of using emotional intelligence within a